Patents by Inventor Avi J. Ashkenazi

Avi J. Ashkenazi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APO-2 receptor polypeptides
    Patent number: 7939631
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: May 10, 2011
    Assignee: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • ANTIBODIES TO APO-2 RECEPTOR POLYPEPTIDES
    Publication number: 20110008354
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: August 19, 2010
    Publication date: January 13, 2011
    Applicant: GENENTECH, INC.
    Inventors: CAMELLIA W. ADAMS, AVI J. ASHKENAZI, ANAN CHUNTHARAPAI, KYUNG JIN KIM
  • APO-2 RECEPTOR POLYPEPTIDES
    Publication number: 20110009599
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: March 1, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Methods for making Apo-2 ligand using divalent metal ions
    Patent number: 7855066
    Abstract: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: December 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Sarah Hymowitz, Robert F. Kelley, Iphigenia Koumenis, Woon-Lam Susan Leung, Mark O'Connell, Roger Pai, Zahra Shahrokh, Laura Simmons
  • Apo-2DcR
    Publication number: 20100273257
    Abstract: Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.
    Type: Application
    Filed: January 15, 2009
    Publication date: October 28, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Kevin P. Baker, Anan Chuntharapai, Austin Gurney, Kyung Jin Kim, William I. Wood
  • Apo-2DcR
    Publication number: 20100269184
    Abstract: Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.
    Type: Application
    Filed: December 10, 2009
    Publication date: October 21, 2010
    Inventors: Avi J. Ashkenazi, Kevin P. Baker, Austin Gurney, William I. Wood
  • Apo-2 receptor agonist antibodies
    Patent number: 7807153
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: October 5, 2010
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
  • Apo-2 receptor polypeptides
    Patent number: 7750118
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: July 6, 2010
    Assignee: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Apo-2 receptor polynucleotides
    Patent number: 7749755
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: July 6, 2010
    Assignee: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Assays and methods using biomarkers
    Publication number: 20100158856
    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.
    Type: Application
    Filed: October 23, 2009
    Publication date: June 24, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Klaus W. Wagner
  • APO-2 RECEPTOR FUSION PROTEINS
    Publication number: 20100152426
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: July 11, 2006
    Publication date: June 17, 2010
    Inventor: Avi J. Ashkenazi
  • METHODS AND COMPOSITIONS RELATING TO ZPA POLYPEPTIDES
    Publication number: 20100150928
    Abstract: The present invention provides ZPA polypeptides, antibodies, nucleic acid molecules, antagonists, agonists, potentiators and compositions relating to ZPA polypeptides, and methods of identifying, making and using the same, that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides model systems for the intrinsic apoptotic pathway.
    Type: Application
    Filed: May 3, 2007
    Publication date: June 17, 2010
    Applicant: Geneetech, Inc.
    Inventors: Avi J. Ashkenazi, Reece Hart, Erica Kratz, Kiran Mukhyala
  • Compositions and Methods for the Diagnosis and Treatment of Tumor
    Publication number: 20100145027
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: February 8, 2010
    Publication date: June 10, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Dan L. Eaton, Audrey Goddard, Austin L. Gurney, William I. Wood, Thomas D. Wu
  • Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
    Publication number: 20100136624
    Abstract: A method of making monoclonal antibodies according to a mixed antigen immunization protocol is described. In addition, antibodies obtainable by the method are disclosed which specifically cross-react with two or more different receptors to which Apo-2 ligand (Apo-2L) can bind.
    Type: Application
    Filed: July 30, 2009
    Publication date: June 3, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Anan Chuntharapai, K. Jin Kim
  • Screening method
    Patent number: 7705195
    Abstract: The present invention is directed to methods using transgenic mice to screen for biologically active agents.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: April 27, 2010
    Assignee: Genentech, Inc.
    Inventors: Dorothy French, Avi J. Ashkenazi, Jean-Philippe F. Stephan, Luc Desnoyers
  • Antibodies that bind TAT294
    Patent number: 7691978
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: April 6, 2010
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Dan L. Eaton, Audrey Goddard, Austin L. Gurney, William I. Wood, Thomas D. Wu
  • DcR3 polypeptide, A TNFR homolog
    Publication number: 20100080793
    Abstract: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.
    Type: Application
    Filed: October 14, 2008
    Publication date: April 1, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, David Botstein, Kelly H. Dodge, Audrey Goddard, Austin L. Gurney, Kyung Jim Kim, David A. Lawrence, Robert Pitti, Margaret A. Roy, Daniel B. Tumas, William I. Wood
  • Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
    Publication number: 20100010195
    Abstract: The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: April 8, 2009
    Publication date: January 14, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Audrey Goddard, Austin Gurney, Scot A. Marsters, Robert M. Pitti, William I. Wood
  • Methods of using death receptor ligands and cd20 antibodies
    Publication number: 20090317384
    Abstract: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and CD20 antibodies to treat conditions such as cancer and immune related diseases are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with CD20 antibodies.
    Type: Application
    Filed: September 7, 2005
    Publication date: December 24, 2009
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Assays and methods using biomarkers
    Patent number: 7629136
    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: December 8, 2009
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Klaus W. Wagner